Physician profile
Kimberly Meyer
NPI 1346233970
$2,871.19
in general payments reported to CMS, 2019-2025
15 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $109 · 2023: $167 · 2024: $797 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $793.94 | 2021-2025 | Pipeline, Strata, Duet |
| Balt USA, LLC | $526.65 | 2022-2025 | Optima Coil System |
| Stryker Corporation | $475.02 | 2024-2025 | Surpass Evolve, Target |
| Microvention, INC. | $334.03 | 2025 | Web Aneurysm Embolization System, Stent, Balloon Catheter |
| Penumbra, INC. | $236.78 | 2025 | Red 72 |
| Astrazeneca Pharmaceuticals LP | $140.32 | 2021-2022 | |
| Gt Medical Technologies, INC | $139.57 | 2024 | Gammatile |
| Servier Pharmaceuticals LLC | $46.17 | 2025 | |
| Novocure INC. | $44.03 | 2024 | Optune |
| Merz Pharmaceuticals, LLC | $42.94 | 2024-2025 | Xeomin, Inbrija |
| Cordis US Corp. | $20.57 | 2025 | |
| Genentech USA, INC. | $20.41 | 2025 | Polivy |
| Amgen INC. | $19.98 | 2025 | |
| Lilly USA, LLC | $15.87 | 2024 | Zepbound, Jardiance |
| Abbvie INC. | $14.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.